



2a



2b

Supplementary Fig. 2 a and b

Asparaginase (ASP) levels day 3 (2a) and day 7 (2b) after 5000 U/m<sup>2</sup> and 10000 U/m<sup>2</sup> Asparaginase medac<sup>TM</sup> IM in serum of samples collected from patients treated in trial MB 2008 (Trial-Registry No. NCT01953770). Included were patients who had at least 2 measurements on day 3 and day 7 each, i.e. at least 4 measurements. Day 3 (N = 100 after 5000 U/m<sup>2</sup>, 897 samples; N = 113 after 10000 U/m<sup>2</sup>, 968 samples); day 7 (N = 100 after 5000 U/m<sup>2</sup>, 837 samples; N = 113 after 10000 U/m<sup>2</sup>, 915 samples).

On day 3, ASP levels of  $\geq 100$  U/L were measured in 81% and 88% of samples after 5000 U/m<sup>2</sup> and 10000 U/m<sup>2</sup>, respectively, ( $p < 0,01$ ). On day 7, ASP levels of  $\geq 100$  U/L were found in 10% and 16% of samples after 5000 U/m<sup>2</sup> and 10000 U/m<sup>2</sup>, respectively, ( $p < 0,01$ ).